Global Glaucoma Surgery Devices Market Size By Type (Ultrasound Equipment, Laser Equipment), By Application (Hospital, Physical Examination Center), By Region, And Segment Forecasts, 2023 to 2032

The Global Glaucoma Surgery Devices Market was valued at USD 1.6 billion in 2023 and is expected to surpass USD 3.4 billion by 2031, growing at a CAGR of 9.8% during the forecast period from 2023 to 2031. Glaucoma surgery devices are essential in managing intraocular pressure (IOP) in patients where medications and laser treatments prove insufficient. The growing prevalence of glaucoma globally, especially among the aging population, along with technological advancements in minimally invasive glaucoma surgery (MIGS) devices, are primary factors driving market expansion.

Drivers:

1. Rising Prevalence of Glaucoma:

Glaucoma affects over 76 million people globally, and this number is expected to increase due to an aging global population. The need for effective surgical interventions, particularly in advanced-stage glaucoma, is accelerating the demand for glaucoma surgery devices.

2. Advancements in MIGS Technology:

The adoption of MIGS devices has revolutionized glaucoma treatment by offering safer and less invasive alternatives to traditional surgery. Their favorable risk-benefit profile has made them increasingly popular among ophthalmologists and patients alike.

3. Growing Awareness and Screening Programs:

Increased efforts in early glaucoma detection through national screening initiatives and awareness campaigns have improved diagnosis rates, leading to timely surgical intervention using advanced devices.

Restraints:

1. High Cost of Surgical Devices and Procedures:

The cost of glaucoma surgical interventions, including devices and hospitalization, can be prohibitive, especially in low- and middle-income countries, limiting access for large patient populations.

2. Limited Access to Specialized Eye Care in Developing Regions:

Shortage of trained ophthalmic surgeons and underdeveloped healthcare infrastructure in some regions hamper the widespread adoption of surgical treatments for glaucoma.

Opportunity:

1. Market Penetration in Emerging Economies:

As healthcare access and ophthalmic care infrastructure improve in Asia-Pacific and Latin America, significant growth opportunities emerge for market players to introduce cost-effective surgical solutions.

2. Integration of Smart Technologies:

The integration of digital technologies and data tracking into glaucoma surgery devices, such as implantable sensors for IOP monitoring, is creating opportunities for innovation and improved postoperative management.

Market by System Type Insights:

Based on system type, the Minimally Invasive Glaucoma Surgery (MIGS) Devices segment accounted for the largest share in 2023. The rising preference for MIGS is driven by its safety profile, rapid recovery, and effectiveness in reducing IOP. The segment is projected to maintain dominance due to continuous innovation and expanding indications for use.

Market by End-use Insights:

In terms of end-use, the Hospitals & Ophthalmology Clinics segment held the highest market share in 2023. The presence of skilled professionals, advanced infrastructure, and growing number of glaucoma surgeries performed in these settings support this segment’s leadership. The Ambulatory Surgical Centers (ASCs) segment is expected to witness the highest growth rate, fueled by cost-efficiency and reduced hospital stays.

Market by Regional Insights:

Geographically, North America led the glaucoma surgery devices market in 2023, owing to high awareness, reimbursement coverage, and rapid adoption of advanced surgical technologies. However, Asia-Pacific is projected to grow at the fastest pace during the forecast period, driven by a large patient base, increasing healthcare investments, and expanding access to ophthalmic care.

Competitive Scenario:

Leading players in the Global Glaucoma Surgery Devices Market include:

Alcon Inc.

Glaukos Corporation

Ivantis Inc. (acquired by Alcon)

New World Medical

Santen Pharmaceutical Co., Ltd.

Johnson & Johnson Vision

Ellex Medical Lasers Ltd.

Allergan (AbbVie)

These companies focus on developing innovative MIGS devices, expanding their product portfolios through M&A, and strengthening their global distribution networks.

Scope of Work – Global Glaucoma Surgery Devices Market

Report Metric Details

Market Size (2023) USD 1.6 billion

Projected Market Size (2031) USD 3.4 billion

CAGR (2023-2031) 9.8%

Market Segments By System Type (MIGS, Traditional Devices), By End-use (Hospitals & Clinics, ASCs), By Region

Growth Drivers Increasing prevalence of glaucoma, technological advancements in MIGS, rising awareness

Opportunities Penetration in emerging markets, digital integration in devices

Key Market Developments:

2023: Alcon received expanded FDA approval for its Hydrus Microstent for broader glaucoma indications.

2023: Glaukos announced its next-generation iStent infinite received CE mark approval, enhancing its presence in the European market.

2024: Santen Pharmaceutical collaborated with a leading AI diagnostic firm to improve glaucoma screening and early surgical decision-making in Asia.

FAQs:

1. What is the current market size of the Global Glaucoma Surgery Devices Market?

The market was valued at USD 1.6 billion in 2023.

2. What is the major growth driver of the Global Glaucoma Surgery Devices Market?

The primary driver is the increasing prevalence of glaucoma and rising adoption of minimally invasive glaucoma surgery (MIGS) devices.

3. Which is the largest region during the forecast period in the Global Glaucoma Surgery Devices Market?

North America holds the largest share, while Asia-Pacific is expected to grow at the fastest rate.

4. Which segment accounted for the largest market share in the Global Glaucoma Surgery Devices Market?

The MIGS Devices segment accounted for the largest share in 2023.

5. Who are the key market players in the Global Glaucoma Surgery Devices Market?

Key players include Alcon, Glaukos Corporation, New World Medical, Santen Pharmaceutical, and Johnson & Johnson Vision.